Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.32 |
| ▸ | GSK3B | P49841 | 1/20 | 0.32 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.32 |
| ▸ | EED | O75530 | 1/20 | 0.32 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.32 |
| ▸ | KDR | P35968 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.31 |
| ▸ | GRM5 | P41594 | 2/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
| ▸ | PRTN3 | P24158 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31436000 | 0.90 | ELANE (0.33) | PTGDR2GSK3AGSK3BPCSK9ELANE | |
| SCHEMBL31435946 | 0.88 | PTGS2 (0.35) | PTGDR2LMNAIDO1TDO2EED | |
| SCHEMBL31435958 | 0.85 | DGAT1 (0.33) | GSK3AGSK3BKDRPTGS2 | |
| SCHEMBL31396578 | 0.83 | PTGDR2 (0.37) | PTGDR2LMNAPCSK9EEDTP53 | |
| SCHEMBL31436019 | 0.80 | PTPN11 (0.46) | IDO1TDO2EEDPDGFRBKDR | |
| SCHEMBL31396603 | 0.74 | MAPT (0.36) | PTGDR2LMNAPCSK9EEDTP53 | |
| SCHEMBL31396494 | 0.74 | MAPT (0.37) | PTGDR2LMNAPCSK9EEDTP53 | |
| SCHEMBL31435956 | 0.72 | ELANE (0.36) | PTGDR2PCSK9MAPTELANE | |
| SCHEMBL20576447 | 0.71 | AGTR1 (0.39) | PTGDR2LMNAIDO1TDO2MAPT | |
| SCHEMBL31396477 | 0.70 | PTGDR2 (0.35) | PTGDR2LMNAPCSK9MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | HALIA THERAPEUTICS INC (US) | 2025-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019378-A1 | PYRROLE[2,3-B]PYRIDINE DERIVATIVES AS TYRO3 INHIBITORS | TYRO3, TH, TYR | PTGDR2 1637/4885LMNA 3596/4885IDO1 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.